Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

The company’s current venue, the respiratory system. Dr. Jonathan C. Javitt MD, MPH mentioned new exciting projects (or bridge studies...???) at the time, in 3 - 6 months, or Feb - May. WHAT NEW PROJECTS??? COULD IT BE...??? There is mounting evidence that pulmonary arterial hypertension (PAH), asthma and chronic obstructive pulmonary disease (COPD) share important pathological features, including inflammation, smooth muscle contraction and remodeling. No existing drug provides the combined potential advantages of reducing vascular- and bronchial-constriction, and anti-inflammation. Vasoactive intestinal peptide (VIP) is widely expressed throughout the cardiopulmonary system and exerts a variety of biological actions, including potent vascular and airway dilatory actions, potent anti-inflammatory actions, improving blood circulation to the heart and lung, and modulation of airway secretions. VIP has emerged as a promising drug candidate for the treatment of cardiopulmonary disorders such as PAH, asthma, and COPD. Clinical application of VIP has been limited in the past for a number of reasons, including its short plasma half-life and difficulty in administration routes. The development of long-acting VIP analogues, in combination with appropriate drug delivery systems, may provide clinically useful agents for the treatment of PAH, asthma, and COPD. This article reviews the physiological significance of VIP in cardiopulmonary system and the therapeutic potential of VIP-based agents in the treatment of pulmonary diseases. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3090995/ The COPD and asthma devices market size was estimated at $36.45 billion in 2019, and is anticipated to hit $51.62 billion by 2027, registering a CAGR of 4.3% from 2020 to 2027 https://www.globenewswire.com/news-release/2020/08/11/2076489/0/en/COPD-and-Asthma-Devices-Market-Size-to-Grow-51-62-Billion-By-2027-at-4-3-CAGR.html Pulmonary Arterial Hypertension Market Worth $9.8 Billion By 2027 https://www.grandviewresearch.com/press-release/global-pulmonary-arterial-hypertension-pah-market-size-report